Protagenic Therapeutics Prepares for Nasdaq Delisting, OTC Trading

Protagenic Therapeutics ( (PTIX) ) just unveiled an announcement.

On December 31, 2025, Protagenic Therapeutics received notice from Nasdaq that trading of its common stock and warrants would cease on Nasdaq at the close of trading on January 2, 2026, due to the company’s failure to meet continued listing requirements related to minimum stockholders’ equity and timely filing of periodic reports. Beginning January 5, 2026, the company expects its securities to be quoted and traded on the over-the-counter market, a shift that may affect liquidity and trading dynamics for investors, while Protagenic plans to continue filing SEC reports, evaluate steps to regain compliance with Nasdaq standards, seek a potential relisting, and work with market participants to support trading in its securities following the final delisting determination and withdrawal of its Nasdaq hearing request.

Spark’s Take on PTIX Stock

According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.

Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.

To see Spark’s full report on PTIX stock, click here.

More about Protagenic Therapeutics

Protagenic Therapeutics, Inc. is a publicly traded biotechnology company whose common stock (PTIX) and warrants (PTIXW) have been listed on the Nasdaq Capital Market, providing investors with exposure to its shares through a national securities exchange.

Average Trading Volume: 112,424

Technical Sentiment Signal: Sell

Current Market Cap: $1.43M

For detailed information about PTIX stock, go to TipRanks’ Stock Analysis page.